• Entela Kolovani Infectious Diseases Clinic, University Hospital Center “Mother Teresa”, Tirana, Albania
  • Ergys Ramosaço Faculty of Technical Medical Sciences, University of Medicine
  • Rovena Byku Infectious Diseases Clinic, University Hospital Center “Mother Teresa”
  • Najada Çomo Infectious Diseases Clinic, University Hospital Center “Mother Teresa”
  • Rezart Xhani Urology Clinic, University Hospital Center “Mother Teresa“
  • Ervin Rrapushi Rheumatology Clinic, University Hospital Center “Mother Teresa“
  • Dhimiter Kraja Infectious Diseases Clinic, University Hospital Center “Mother Teresa”
Keywords: Bladder carcinoma, BCG immunotherapy, Reiter’s syndrome, diagnose


Intravesical Bacillus Calmette-Guérin immunotherapy is an effective agent for superficial bladder carcinoma. The main adverse effect of this treatment is cystitis. Arthralgia and migratory arthritis occur only in 0.5% of patients. Reiter syndrome is a very rare complication that can occur after intravesical apply of Bacillus Calmette-Guérin Immunotherapy. We report the first Albanian patient who developed Reiter’s syndrome, following intravesical Bacillus Calmette-Guérin. Diagnose of Reiter’s Syndrome was clinically based, excluding every other reason that could have caused it. Treatment was made with non-steroid and steroid anti-inflammatory drugs, followed by a full recovery result. Even though Reiter's Syndrome is a rare, but significant complication of BCG immunotherapy, it’s important to identify it in time, in order we to offer an adequate treatment.  


Barmoshe S, et al. (2004). Prognosis of T1G3 tumors: clinical factors. Eur Urol Suppl. 3:73–8.

Bernini L, et al (2013). Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature. Autoimmun Rev. 12(12):1150–1159

Brausi M, et al. (2014). Side effects of bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 65(1):69–76.

Decaestecker K, et al. (2015). Managing the adverse events of intravesical bacillus Calmette–Guérin therapy. Res Rep Urol. 7: 157–163.

Herr HW, et al (1989). Superficial bladder cancer treated with bacillus Calmette-Guérin: A multivariate analysis of factors affecting tumor progression. J Urol. 141:22–9

Hogarth M B, et al. (2000). Reiter’s syndrome following intravesical BCG Immunotherapy. Postgrad Med J 2000;76:791–795)

Keng Lim Ng a,b, et al (2017). Reiter’s syndrome postintravesical Bacillus Calmettee Gue´rin instillations.Asian Journal of Surgery Volume 40, Issue 2, Pages 163-165

Murata H, et al. (2004). Reiter’s syndrome following intravesical bacille bilié de Calmette–Guérin treatment for superficial bladder carcinoma: report of six cases. Mod Rheumatol 14:82–86

Pancaldi P, et al. (1993). Reiter’s syndrome after intravesical Bacillus Calmette-Guerin treatment for superficial bladder carcinoma. Br J Rheumatol ;32:1096–8.

Palnæs Hansen CP, et al. (1997). Epididymo-orchitis and Reiter’s disease. Two infrequent complications after intravesical Bacillus Calmette-Guerin therapy. Scand J Urol Nephrol; 31:317–18.

Spence. R. et al. (2006). Infection in the Cancer Patient a Practical Guide, Oxford University Press.

Sylvester RJ, et al. (2002). Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. Nov. 168(5):1964-70.

Selmi C, et al (2014). Gershwin ME; Diagnosis and classification of reactive arthritis. Autoimmun Rev. Apr-May 13(4-5):546-9.

Saporta L, et al.(1996). Reiter syndrome following intracavitory BCG administration. Scand J Urol Nephrol ;31:211–12.